Published in Cancer Weekly, October 18th, 2005
"Human MCL, an aggressive B cell non-Hodgkin lymphoma, is characterized by the overexpression of cyclin D1 which plays an essential role in the survival and proliferation of MCL. Because of MCL's resistance to current chemotherapy, novel approaches are needed," scientists in the United States reported.
"Since MCL cells are known to overexpress NF-kappa B regulated gene products (including cyclin D1), we used curcumin, a pharmacologically safe agent, to target NF-kappa B in a variety of MCL cell lines. All four MCL cell lines examined had overexpression of cyclin D1,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.